Talquetamab shot for elderly with relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has come back or not responded to treatment after at least 2 previous therapies.
- You must not have received any prior T-cell-engaging antibody therapy (a type of immunotherapy).
- You must not have had a stem cell transplant within the last 12 weeks or any prior allogeneic (donor) transplant.
- Your kidney function (eGFR) must be 30 or higher, and your blood counts (hemoglobin, platelets, neutrophils) must be at certain minimum levels.
- You cannot have other uncontrolled serious illnesses, like active infections, heart problems, or certain other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
This study tests a drug called talquetamab for people with multiple myeloma who have already had a type of immunotherapy called CAR T-cell therapy (ide-cel). The goal is to see if talquetamab can help control the cancer after the CAR T cells have had time to work.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
This trial tests a combination of two drugs, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination works better than using one drug alone.
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.